Sign Out
Hypersensitivity to any component of Avas. Active liver disease or unexplained persistent elevations of serum transaminase exceeding 3 times the upper limit of normal.
Use in pregnancy & lactation: Safety in pregnancy has not been established. Rare reports of congenital anomalies have been reported following intrauterine exposure of HMG-CoA reductase inhibitors. HMG-CoA reductase inhibitors are not recommended for use during pregnancy. An interval of 1 month should be allowed from stopping Avas treatment to conception in the event of planning a pregnancy.
Use of HMG-CoA reductase inhibitors during breastfeeding is not recommended, because of the potential for serious adverse effects in nursing infants.
